MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come first.
News|Articles|September 1, 2026
5 Essential Capabilities for Decentralized Clinical Trials
Author(s)Quest Diagnostics
Advertisement
As the clinical research landscape evolves, decentralized clinical trials (DCTs) have emerged as a foundational competency, enabling broader patient participation, increasing trial efficiency, and driving more inclusive, real-world data collection. However, the successful execution of DCTs requires more than just innovative technology—it demands a comprehensive strategy that addresses the unique challenges of decentralization.
Advertisement
Related to this article
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Advertisement
Advertisement
Trending on PharmExec
1
Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion
2
Hansoh Pharma Enters $15 Billion Collaboration and License Agreement with Roche
3
Is Participation in MFN Voluntary?
4
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
5